Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
NCT05651100
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, B-Cell
Interventions
BIOLOGICAL:
CD19 and CD22 targeted CAR-T cells
Sponsor
Kecellitics Biotech Company Ltd
Collaborators
[object Object]